Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 2, Randomized, Double-blind Placebo-controlled Study to Test the Efficacy and Safety of KPL-301 in Giant Cell Arteritis

Trial Profile

A Phase 2, Randomized, Double-blind Placebo-controlled Study to Test the Efficacy and Safety of KPL-301 in Giant Cell Arteritis

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 19 Oct 2023

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Mavrilimumab (Primary) ; Prednisone
  • Indications Giant cell arteritis
  • Focus Proof of concept; Therapeutic Use
  • Sponsors Kiniksa Pharmaceuticals
  • Most Recent Events

    • 09 Mar 2022 Results published in the Annals of the Rheumatic Diseases
    • 09 Nov 2021 Results of post hoc analysis assessing the CRP and ESR levels from randomization through Wk 26 in patients with and without relapse by treatment arm presented at the ACR Convergence 2021
    • 01 Nov 2021 According to a Kiniksa Pharmaceuticals media release, data from this trial will be presented at the upcoming American College of Rheumatology (ACR) Convergence 2021.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top